Biogen to urgently appeal court judgment allowing generic MS drug
High Court decision would pave the way for the sale of a generic multiple sclerosis drug and save the HSE over €8 million, but pharma giant claims the firm behind the drug is infringing on its patent
Biogen, the pharma giant, has pledged to urgently appeal a High Court decision which would pave the way for the sale of a generic multiple sclerosis (MS) drug in Ireland and save the HSE over €8 million.
The company had sought an injunction against companies linked to the Neuraxpharm group to prevent the sale of a generic MS drug pending a full trial on the validity of a patent. While it was refused the injunction, ...